BRPI1006869A2 - estimuladores de sgc ou ativadores da sgc em combinação com inibidores da pde5 para o tratamento de disfunção erétil - Google Patents

estimuladores de sgc ou ativadores da sgc em combinação com inibidores da pde5 para o tratamento de disfunção erétil

Info

Publication number
BRPI1006869A2
BRPI1006869A2 BRPI1006869A BRPI1006869A BRPI1006869A2 BR PI1006869 A2 BRPI1006869 A2 BR PI1006869A2 BR PI1006869 A BRPI1006869 A BR PI1006869A BR PI1006869 A BRPI1006869 A BR PI1006869A BR PI1006869 A2 BRPI1006869 A2 BR PI1006869A2
Authority
BR
Brazil
Prior art keywords
sgc
treatment
combination
erectile dysfunction
pde5 inhibitors
Prior art date
Application number
BRPI1006869A
Other languages
English (en)
Inventor
Johannes-Peter Stasch
Michael-Friedrich Böttcher
Peter Sandner
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of BRPI1006869A2 publication Critical patent/BRPI1006869A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI1006869A 2009-01-17 2010-01-07 estimuladores de sgc ou ativadores da sgc em combinação com inibidores da pde5 para o tratamento de disfunção erétil BRPI1006869A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09000619 2009-01-17
EP09002177 2009-02-17
PCT/EP2010/000029 WO2010081647A2 (en) 2009-01-17 2010-01-07 Sgc stimulators of sgc activators in combination with pde5 inhbitors for the treatment of erectile dysfunction

Publications (1)

Publication Number Publication Date
BRPI1006869A2 true BRPI1006869A2 (pt) 2016-03-15

Family

ID=42153923

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1006869A BRPI1006869A2 (pt) 2009-01-17 2010-01-07 estimuladores de sgc ou ativadores da sgc em combinação com inibidores da pde5 para o tratamento de disfunção erétil

Country Status (20)

Country Link
US (2) US20120022028A1 (pt)
EP (1) EP2387404B1 (pt)
JP (1) JP5780430B2 (pt)
KR (1) KR20110117655A (pt)
CN (1) CN102316870A (pt)
AU (1) AU2010205931A1 (pt)
BR (1) BRPI1006869A2 (pt)
CA (1) CA2749730C (pt)
CL (1) CL2011001712A1 (pt)
EA (1) EA201170942A1 (pt)
ES (1) ES2493718T3 (pt)
IL (1) IL213857A0 (pt)
MA (1) MA32967B1 (pt)
MX (1) MX2011007515A (pt)
SG (1) SG172841A1 (pt)
SV (1) SV2011003973A (pt)
TN (1) TN2011000349A1 (pt)
TW (1) TW201036971A (pt)
WO (1) WO2010081647A2 (pt)
ZA (1) ZA201105085B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011095553A1 (en) * 2010-02-05 2011-08-11 Bayer Schering Pharma Aktiengesellschaft Sgc stimulators or sgc activators in combination with pde5 inhbitors for the treatment of erectile dysfunction
CA2800709C (en) 2010-05-26 2017-04-04 Claudia Hirth-Dietrich The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of systemic sclerosis (ssc)
EP2585055A1 (de) * 2010-06-25 2013-05-01 Bayer Intellectual Property GmbH Verwendung von stimulatoren und aktivatoren der löslichen guanylatzyklase zur behandlung von sichelzellanämie und konservierung von blutersatzstoffen
JP5715713B2 (ja) 2011-03-10 2015-05-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 可溶性グアニル酸シクラーゼ活性化因子
WO2013025425A1 (en) 2011-08-12 2013-02-21 Boehringer Ingelheim International Gmbh Soluble guanylate cyclase activators
KR101960100B1 (ko) * 2011-12-08 2019-03-19 에스케이케미칼 주식회사 미로데나필 또는 이의 약학적으로 허용 가능한 염을 함유하는 구강 투여용 필름
CA2880494C (en) 2012-09-07 2021-09-21 Boehringer Ingelheim International Gmbh Alkoxy pyrazoles as soluble guanylate cyclase activators
EP3024455A1 (en) 2013-07-25 2016-06-01 Bayer Pharma Aktiengesellschaft Sgc stimulators or sgc activators and pde5 inhibitors in combination with additional treatment for the therapy of cystic fibrosis
EP3082428A4 (en) 2013-12-09 2017-08-02 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
WO2016014463A1 (en) 2014-07-22 2016-01-28 Boehringer Ingelheim International Gmbh Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
ES2912648T3 (es) 2015-11-16 2022-05-26 Topadur Pharma Ag Derivados de 2-fenil-3,4-dihidropirrolo[2,1-f] [1,2,4]triazinona como inhibidores de la fosfodiesterasa y usos de los mismos
AU2018274599B9 (en) 2017-05-22 2022-04-07 Topadur Pharma Ag Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof
BR112021009958A2 (pt) 2018-11-28 2021-08-17 Topadur Pharma Ag modo duplo de ação de ativadores de guanilato ciclase solúveis e inibidores de fosfodiesterase e seus usos
CN110305837A (zh) * 2019-06-05 2019-10-08 西北师范大学 磷酸二酯酶5活性抑制剂作为诱导斑马鱼***成熟的催熟剂的应用
WO2021245192A1 (en) 2020-06-04 2021-12-09 Topadur Pharma Ag Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB371800A (en) 1929-10-21 1932-04-28 Willem Zaadnoordijk A process of filtering gases and fogs
GB369003A (en) 1931-03-25 1932-03-17 Richard Henry Sansome Improvements in fire extinguishing fluids
DE69928260T2 (de) * 1998-07-08 2006-07-20 Sanofi-Aventis Deutschland Gmbh Schwefel-substituierte sulfonylaminocarbonsäure n-arylamide, ihre herstellung, ihre anwendung und diese enthaltende pharmazeutische zusammensetzungen
DE19834044A1 (de) * 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19943635A1 (de) * 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10220570A1 (de) * 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
WO2008124505A2 (en) * 2007-04-05 2008-10-16 Ironwood Pharmaceuticals,Inc. Soluble guanylate cyclase (sgc) modulators for treatment of lipid related disorders
BRPI0811581A2 (pt) * 2007-05-12 2014-12-09 Bayer Schering Pharma Ag Estimuladores de sgc, ativadores de sgc e combinações para o tratamento de distúrbios urológicos

Also Published As

Publication number Publication date
SG172841A1 (en) 2011-08-29
JP2012515176A (ja) 2012-07-05
MX2011007515A (es) 2011-08-12
TN2011000349A1 (en) 2013-03-27
AU2010205931A1 (en) 2011-07-28
JP5780430B2 (ja) 2015-09-16
CL2011001712A1 (es) 2012-04-09
KR20110117655A (ko) 2011-10-27
WO2010081647A2 (en) 2010-07-22
EP2387404A2 (en) 2011-11-23
ZA201105085B (en) 2012-09-26
MA32967B1 (fr) 2012-01-02
EP2387404B1 (en) 2014-06-25
CA2749730A1 (en) 2010-07-22
CN102316870A (zh) 2012-01-11
TW201036971A (en) 2010-10-16
IL213857A0 (en) 2011-07-31
EA201170942A1 (ru) 2012-02-28
WO2010081647A3 (en) 2010-10-21
US20120022028A1 (en) 2012-01-26
ES2493718T3 (es) 2014-09-12
SV2011003973A (es) 2011-12-06
US20140288079A1 (en) 2014-09-25
CA2749730C (en) 2017-02-14

Similar Documents

Publication Publication Date Title
BRPI1006869A2 (pt) estimuladores de sgc ou ativadores da sgc em combinação com inibidores da pde5 para o tratamento de disfunção erétil
IL230683A0 (en) dpp-iv inhibitors for use in the treatment of nafld
BRPI1013698A2 (pt) métodos para tratamento com o uso de terapia de combinação
ME02207B (me) UPOTREBA sGC STIMULATORA, sGC AKTIVATORA, POJEDINAČNO I U KOMBINACIJI SA PDE5 INHIBITORIMA ZA TRETMAN SISTEMSKE SKLEROZE (SSc)
HK1170737A1 (zh) 萘啶衍生物及其作為激酶抑制劑的用途
BRPI1011066A2 (pt) "pirazolopirimidinas e heterociclos relacionados como inibidores de quinase
SMT201500286B (it) STIMOLATORI DI sGC O ATTIVATORI DI sGC DA SOLI O IN COMBINAZIONE CON INIBITORI DI PDE5 PER IL TRATTAMENTO DELLA FIBROSI CISTICA
IL220086A0 (en) Pyrazolopyrimidines and related heterocycles as ck2 inhibitors
IL211549A (en) Aminotriazolopyridines and their uses as kinase inhibitors
BR112012004149A2 (pt) terapia de combinação com composições de nanopartículas de taxano e inibidores de hedgehog
ZA201001193B (en) 2-anilinopurin-8-ones as inhibitors of TTK/MPS1 for the treatment of proliferative disorders
HK1153926A1 (en) Purin derivatives for use in the treatment of fab-related diseases fab-
PT2658551T (pt) Tratamento da disfunção erétil e outras indicações
IL207127A0 (en) Aldh-2 inhibitors in the treatment of addiction
HK1244706A1 (zh) 用於治療***功能障礙的組成物及方法
HK1256479A1 (zh) 在治療癌症中grn163l用作端粒酶抑制劑
GB201211237D0 (en) CDK5 inhibitors and therapeutic uses thereof
EP2456437A4 (en) COMBINATION THERAPY FOR TAUOPATHIES
ES2389424B1 (es) Procedimiento para la visualizacion de superficies en el cuerpo humano.
IT1391451B1 (it) Preparato per il trattamento della disfunzione erettile
TH114429B (th) การใช้แบคทีเรียแลคติกในการรักษาหรือป้องกันโรคผิวหนังอักเสบ
UA36331U (ru) Применение рисперидона как средства для лечения опиоидной зависимости
TH141460A (th) การใช้สารกระตุ้น sGC, สารปลุกฤทธิ์ sGC เพียงสารเดียวและใช้ร่วมกับสารยับยั้ง PDE5 เพื่อรักษาโรคหนังแข็ง (SSc) (The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc))

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A, 5A E 6A ANUIDADES.

B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]